Evidence map›Paper›PMID 36503354›Full record

ArticleHuman vaccines & immunotherapeutics2022

Correlative outcomes of maternal immunization against RSV in cotton rats.

Jorge C G Blanco, Lori M Cullen, Arash Kamali, Fatoumata Y D Sylla, Zenab Chinmoun, Marina S Boukhvalova, Trudy G Morrison

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jorge C G BlancoResearch Department, Sigmovir Biosystems Inc. Rockville, Rockville, MD, USA.
Lori M CullenDepartment of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Arash KamaliResearch Department, Sigmovir Biosystems Inc. Rockville, Rockville, MD, USA.
Fatoumata Y D SyllaResearch Department, Sigmovir Biosystems Inc. Rockville, Rockville, MD, USA.
Zenab ChinmounResearch Department, Sigmovir Biosystems Inc. Rockville, Rockville, MD, USA.
Marina S BoukhvalovaResearch Department, Sigmovir Biosystems Inc. Rockville, Rockville, MD, USA.
Trudy G MorrisonDepartment of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Sigmovir Biosystems (United States) · USUniversity of Massachusetts Chan Medical School · US

Funding

Development of an RSV vaccine for the elderlyR01AI143896 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MORRISON, TRUDY G. · 2020 to 2024
$3.6M
Development of VLP vaccine for RSVR44AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2019 to 2021
$3.5M
Development of VLP vaccine for RSVR42AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2016 to 2017
$1.9M
Development of VPL Vaccine for RSVR41AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2014 to 2014
$225k
NIAID NIH HHS R01 AI143896NIAID NIH HHS R41 AI109926NIAID NIH HHS R42 AI109926NIAID NIH HHS R44 AI109926
6 · The paper itself

Abstract

Maternal anti-respiratory syncytial virus (RSV) antibodies protect neonates from RSV disease throughout first weeks of life. Previous studies of maternal immunization in cotton rats showed that a single immunization during pregnancy of RSV-primed dams with virus-like particles (VLPs) assembled with pre-fusion F protein and the wild type G protein boosted their RSV serum antibody concentration and protected pups early in life against RSV challenge. We extended these findings by evaluating responses to RSV infection in litters from two consecutive pregnancies of immunized dams. Using an RSV-primed population of VLP-vaccinated and unvaccinated dams, we defined correlations between dams' and litters' RSV neutralizing antibodies (NA); between litters' NA and protection; and between litter's NA and their lung expression of selected cytokines, of a first or of a second pregnancy. Lung pathology was also evaluated. We found positive correlation between the NA titers in the dams at delivery and the NA in their first and second litters and negative correlations between the litters' NA and protection from RSV challenge. Vaccination of dams modulated the mRNA expression for IFNγ and IL-6 and lung pathology in the first and in the second litter at different times after birth, even in the absence of detectable NA. Maternal RSV vaccination enhanced the levels of antibodies transferred to offspring and their protection from challenge. Importantly, maternal vaccination also impacted the immunological and inflammatory response of the offspring's lungs well into maturity, and after the antiviral effect of maternally transferred NA waned or was no longer detectable.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleImmunizationLungPregnancySigmodontinaeVaccinationViral Fusion ProteinsAntibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus VaccinesViral Fusion Proteinscotton ratMaternal VaccinationpregnancyRSV Vaccination

Identifiers

PMID36503354
PMCPMC9766472
OpenAlexW4312052296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.